Compare PRAX & WAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAX | WAL |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.7B |
| IPO Year | 2020 | 2005 |
| Metric | PRAX | WAL |
|---|---|---|
| Price | $312.37 | $91.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $397.85 | $98.93 |
| AVG Volume (30 Days) | 623.7K | ★ 774.0K |
| Earning Date | 02-27-2026 | 01-26-2026 |
| Dividend Yield | N/A | ★ 1.77% |
| EPS Growth | N/A | ★ 24.99 |
| EPS | N/A | ★ 8.09 |
| Revenue | $7,463,000.00 | ★ $3,189,400,000.00 |
| Revenue This Year | N/A | $16.21 |
| Revenue Next Year | $14,827.76 | $9.13 |
| P/E Ratio | ★ N/A | $10.60 |
| Revenue Growth | ★ 364.98 | 9.57 |
| 52 Week Low | $26.70 | $57.05 |
| 52 Week High | $326.91 | $94.40 |
| Indicator | PRAX | WAL |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 60.44 |
| Support Level | $266.93 | $85.62 |
| Resistance Level | $326.91 | $90.77 |
| Average True Range (ATR) | 17.87 | 2.42 |
| MACD | 0.13 | -0.05 |
| Stochastic Oscillator | 75.94 | 92.64 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.